Herein we report nine cases of carotid endarterectomy in which we used a cold atmospheric helium plasma device (J-Plasma; Apyx Medical Corporation, Clearwater, Fla). Although clinical reports are limited, experimental data indicate that this technology could be used for dissection and coagulation during surgery, yielding limited adjacent tissue damage. As a result, it could be extremely useful in procedures like carotid endarterectomy that necessitate careful dissection and coagulation with limited damage of adjacent neurovascular structures. (J Vasc Surg Cases and Innovative Techniques 2020;6:152-5.) 
Surgical dissection and coagulation by radiofrequency devices or argon plasma are electrosurgical techniques that have been widely used during open or laparoscopic surgery for the last three decades. 1 Their use has been broadly reported for secondary hemostasis or cutdown dissection in different specialties, such as general surgery, dermatology, and gynecology. [2] [3] [4] However, such modalities have been associated with extensive thermal injury of adjacent tissue that prohibits their use in dissection near sensitive neurovascular anatomic structures, especially during specific vascular surgery procedures. 1, 5 Carotid endarterectomy (CEA) remains a vascular surgery procedure that demands precision and surgical skills. Recent pooled data reveal that the rate of cranial nerve injury has been decreased during this procedure, although it still remains a significant complication. 6 Therefore, avoidance of unnecessary thermal damage using traditional electrocautery is of importance, and the application of new technologies could be of benefit during such procedures. A new technology has recently been introduced whereby electrical energy is delivered to tissue through a beam of helium instead of argon gas, providing a lower plasma temperature. 5 This technology is called cold atmospheric helium plasma (CAHP).
J-Plasma (Apyx Medical Corporation, Clearwater, Fla) is such a CAHP device. It uses a gas ionization process to produce a stable, focused beam of ionized helium gas, providing surgeons with greater precision, minimal invasiveness, and absence of conductive currents during surgery. 5 It also has a retractable blade, which allows it to function as a cutting tool that leaves behind almost no tissue damage. When the blade is extended, it cuts down tissue with precision through low-temperature thermal energy produced by the combination of monopolar waveform and flow of helium gas. When the blade is retracted, a noncontact helium "spray" beam is used for ablation or coagulation.
This report describes the promising results with use of the device during CEA, given that there is lack of such evidence in the literature. All patients provided written informed consent for the publication of this case series as well as for all aspects of the procedure. Early outcomes were optimal. There were no deaths, no cerebrovascular events, and no cardiac complications. No cranial nerve injury was observed. All patients were able to speak freely and to move the facial muscles and tongue without any paresis, and they could swallow easily. There were no major bleedings and no surgical site complications. All patients were discharged up to the third postoperative day. No 30-day adverse events have been reported.
CASE REPORT

DISCUSSION
High-frequency electrosurgical devices that cauterize tissues by use of electrical current have been associated with generation of high temperatures, extended adjacent tissue damage, and postoperative complications. [7] [8] [9] Factors influencing the tissue effect are the duration of the application, the power setting of the device, and the distance from the probe to the tissue. 10 Therefore, CAHP technology has been introduced in recent years to ameliorate these disadvantages. The cold plasma effect is highly localized, minimizing temperature levels and collateral damage to surrounding healthy tissue. 11, 12 Moreover, there is no need for a grounding pad, in contrast to standardized electrosurgical devices.
Only a few reports in the literature describe the clinical use of J-Plasma during certain types of procedures, such as oncologic or dermatologic surgery. 13, 14 Furthermore, this device seems to reduce perioperative morbidity, including blood loss, postoperative pain, and overall procedural time in patients undergoing otolaryngologic surgery. 15, 16 J-Plasma also allows safe and effective tissue coagulation, ablation, and incision with controlled precision. 5 In addition, its retractable blade enables greater versatility and control of the energy as well as enhanced visibility at the application site. Thus, this device becomes extremely attractive for procedures necessitating careful dissection and coagulation, such as CEA. These data have motivated us to start using this device, given that its potential risks are similar to those of traditional electrocautery devices. 1, 4 Compared with our previous experience, 17 this technique does not seem to have a negative effect on major outcomes, although a larger number of patients are needed to evaluate the effect on hemostasis time and overall duration of the procedure. Experimental studies on animal models have shown that J-Plasma seems to control oozing bleeding by increasing blood coagulation activity, although it decreases adjacent tissue coagulation. 18 This mechanism is similar to the mechanism of surgical hemostats that stimulate aggregation of platelets and coagulation factors. 19 In a study by Pedroso et al, 20 this specific device was applied on porcine liver, kidney, and muscle tissue at different power levels and gas flows. It was shown that J-Plasma has minimal lateral and depth spread when it is applied to various tissue types, even at higher power settings or gas flow rates. 17 Finally, when J-Plasma is applied to various tissue types, it performs better than or similar to other types of technology, such as monopolar, bipolar, or argon beam. 21 Finally, regarding cost, this device is more expensive than the average electrocautery device. The cost for a J-Plasma probe reaches 500 Euros (taxes included) in Greece per procedure, although the plasma generator is provided for free by the selling company. Although comparative studies in the literature have shown a significantly lower overall cost with low-temperature plasma devices compared with traditional electrocautery, they do not refer to helium gas devices. 22, 23 In addition, the fact that J-Plasma may reduce the overall time of CEA based on our experience shows that overall costs may be reduced. These data are indicative of the cost-effectiveness, although comparative studies specifically of J-Plasma are still needed to support this strategy. Regarding the helium gas, the gas flow during the procedure is small, not exceeding 0.6 L/min. Furthermore, the cost for the gas is included in the price of the probe without additional charges.
CONCLUSIONS
Our results using J-Plasma during CEA procedures are promising. However, clinical studies are necessary to compare the efficacy and safety of this device with other traditional technologies. To achieve this, objective measures of comparison need to be defined for safer conclusions. 
